Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reach...
Main Authors: | Marie-Eve Beaulieu, Sandra Martínez-Martín, Jastrinjan Kaur, Virginia Castillo Cano, Daniel Massó-Vallés, Laia Foradada Felip, Sergio López-Estévez, Erika Serrano del Pozo, Hugo Thabussot, Laura Soucek |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/3/826 |
Similar Items
-
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
by: Daniel Massó-Vallés, et al.
Published: (2020-04-01) -
Finding MYCure
by: Marie-Eve Beaulieu, et al.
Published: (2019-09-01) -
Targeting c-MYC: a potential non-hormonal therapeutic approach for endometriosis treatment
by: Warren B. Nothnick, et al.
Published: (2023-11-01) -
Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma
by: Jessica Rea, et al.
Published: (2021-07-01) -
Differential Expressions of Protamine 1 (PRM1) and Protamine 2 (PRM2) Genes as Markers of Semen Quality in Pasundan Bulls
by: Santoso, et al.
Published: (2022-11-01)